Scott Anderson
Internal Medicine · Hazelwood, MONPI 1316938764
Payments from drug & device makers
Across 168 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$308
- Sanofi-aventis U.S. LLC$224
- Novo Nordisk$201
- GSK$182
- Lilly USA, LLC$171
- Boehringer Ingelheim$141
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,41299%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 22 | $308 |
| Sanofi-aventis U.S. LLC | 18 | $224 |
| Novo Nordisk | 16 | $201 |
| GSK | 15 | $182 |
| Lilly USA, LLC | 12 | $171 |
| Boehringer Ingelheim | 9 | $141 |
| E.r. Squibb & Sons, L.L.C. | 8 | $138 |
| Astellas Pharma US Inc | 8 | $135 |
| Kowa Pharmaceuticals America, Inc. | 10 | $121 |
| Tris Pharma Inc | 7 | $102 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $95 |
| Boston Scientific | 1 | $91 |
| Amarin Pharma, Inc. | 6 | $83 |
| AstraZeneca | 5 | $71 |
| AbbVie(2 entities) | 3 | $52 |
| Abbott | 3 | $52 |
| Amgen | 2 | $30 |
| Blueprint Medicines Corporation | 2 | $28 |
| Sandoz | 2 | $28 |
| Johnson & Johnson | 2 | $27 |
| Sanofi Pasteur Inc. | 2 | $26 |
| Novartis | 2 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Kaleo, Inc. | 1 | $13 |
| Medtronic | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$2,424 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 12 | $11,646 |
| Gabapentin | 17 | $270 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $242 |
| Atorvastatin Calcium | 53 | $223 |
| Lisinopril | 34 | $157 |
| Levothyroxine Sodium | 20 | $151 |
| Levetiracetam | 14 | $123 |
| Finasteride | 12 | $105 |
| Amlodipine Besylate | 27 | $67 |
| Losartan Potassium | 11 | $64 |
| Rosuvastatin Calcium | 11 | $55 |
| Hydrochlorothiazide | 20 | $48 |
| Metformin Hcl | 16 | $44 |
| Tamsulosin Hcl | 11 | $41 |
| Carvedilol | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $171 | $11,64612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Hazelwood
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.